Lakeview Calls on Quipt's Board to Conduct a Genuine Evaluation of All Strategic Alternatives, Including a Sale and a Serious $3.10 All-Cash Bid.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 22 2025
0mins
Should l Buy QIPT?
Source: Newsfilter
Board's Mismanagement: Lakeview Investment Group criticizes Quipt Home Medical Corp.'s Board for failing to engage with credible bidders and for prioritizing its own interests over shareholder value, leading to significant value destruction.
Shareholder Sentiment: The Board's actions, including issuing equity-based compensation and pursuing litigation against a major shareholder, have alienated investors, who are frustrated with the lack of positive returns and transparency.
Bidder Proposal: A publicly disclosed bidder has made a $3.10 per share offer, which Lakeview believes undervalues the company, and they advocate for a transparent strategic review process to explore a sale at a premium.
Call for Change: Lakeview urges the Board to adopt a credible review process with independent advisors to rebuild trust, warning that all Board members may face removal if the current situation continues.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QIPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QIPT
Wall Street analysts forecast QIPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QIPT is 3.77 USD with a low forecast of 3.65 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
1 Hold
1 Sell
Hold
Current: 3.565
Low
3.65
Averages
3.77
High
4.00
Current: 3.565
Low
3.65
Averages
3.77
High
4.00
About QIPT
Quipt Home Medical Corp. provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. The Company's expertise spans across a full spectrum of respiratory care, providing an end-to-end solution for medical providers and patients. This includes technology enabled equipment offerings and specialized care for patients with cardio and pulmonary diseases, sleep disorders, mobility challenges, and other chronic disease management. The Company's healthcare products and services include sleep apnea and pap treatment, home medical equipment, home ventilation and custom mobility solutions. It has a 60% ownership interest in Hart Medical Equipment, which maintains strategic relationships with integrated health systems and freestanding community-based hospitals, embedding the business into the hospital discharge processes of more than 19 hospitals and affiliated care facilities across its network.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quipt Home Medical to Hold Special Shareholder Meeting
- Special Meeting Announcement: Quipt Home Medical will hold a special shareholder meeting on March 3, 2026, to vote on a proposal to acquire all outstanding shares at $3.65 each, representing a 54% premium over the 30-day VWAP as of December 12, 2025, which is expected to significantly enhance shareholder value.
- Voting Support Agreements: The entire board and executive officers of Quipt, holding approximately 11.3% of the shares, have entered into voting support agreements with the acquirer, committing to vote in favor of the arrangement at the meeting, indicating strong management backing for the transaction.
- Interim Court Order: The Supreme Court of British Columbia issued an interim order on January 23, 2026, authorizing the calling of the meeting and setting procedures for its conduct, providing legal assurance for the arrangement's implementation and ensuring compliance.
- Encouragement for Shareholder Voting: Quipt encourages all shareholders to vote by proxy ahead of the February 27, 2026 deadline at 10:00 a.m. (Eastern Standard Time), ensuring that every shareholder's voice is heard and promoting transparency in decision-making.
See More
Quipt Home Medical to Hold Special Shareholder Meeting
- Special Meeting Announcement: Quipt Home Medical will hold a special shareholder meeting on March 3, 2026, where shareholders will vote on a proposal to sell all outstanding shares for $3.65 each, representing a 54% premium over the 30-day VWAP as of December 12, 2025, which could significantly alter the company's shareholder structure and future direction.
- Voting Support Agreements: The entire board and executive officers of Quipt, holding approximately 11.3% of shares, have entered into voting support agreements with the acquirer, committing to vote in favor of the arrangement resolution, which may bolster shareholder confidence in the transaction.
- Interim Order Received: The Supreme Court of British Columbia issued an interim order on January 23, 2026, authorizing the calling of the meeting and establishing procedures for its conduct, providing legal backing for the arrangement's implementation and ensuring the transaction proceeds smoothly.
- Encouragement for Shareholder Voting: The company urges all shareholders to vote in advance of the February 27, 2026, deadline at 10:00 a.m. (Eastern Standard Time), aiming to enhance shareholder engagement and secure the necessary approvals for the transaction to achieve its strategic objectives.
See More
Ademi Firm Investigates Quipt's $260M Transaction with Kingswood for Fiduciary Breaches
- Investigation Launched: The Ademi Firm is investigating Quipt's transaction with Kingswood for potential breaches of fiduciary duty and legal violations, focusing on whether the Quipt board is fulfilling its responsibilities to all shareholders.
- Transaction Valuation: In this deal, Quipt shareholders will receive $3.65 per share, valuing the company at approximately $260 million, including its existing outstanding debt, indicating a significant impact on the company's financial standing.
- Competition Restrictions: The transaction agreement imposes significant penalties on Quipt for accepting competing bids, which could harm shareholder interests and lead to legal disputes regarding the board's conduct.
- Insider Benefits: Quipt insiders will receive substantial benefits as part of the change of control arrangements, raising concerns about the board's actions and potentially affecting the transparency of corporate governance and shareholder trust.
See More
Quipt Home Medical to Sell for $3.65 per Share to Kingswood and Forager
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Quipt Home Medical Corp.'s sale for $3.65 per share, which may violate federal securities laws and impact shareholder rights.
- Merger Transaction Impact: The merger between Fifth Third Bancorp and Comerica Incorporated will result in Fifth Third shareholders owning approximately 73% of the combined entity, potentially altering shareholder control and corporate governance structures.
- Potential Payment Rights: Generation Bio Co. is being sold for $4.2913 per share, along with a non-transferable contingent value right, which could provide shareholders with additional potential payments, enhancing investment appeal.
- Legal Rights Protection: Halper Sadeh LLC offers free consultations to help shareholders understand their legal rights and options, aiming to secure increased consideration and additional disclosures for affected investors.
See More
Monteverde & Associates Investigates Quipt Home Medical Corp. Sale at $3.65 per Share
- Shareholder Rights Protection: Monteverde & Associates is investigating the sale of Quipt Home Medical Corp. to Kingswood Capital Management, where shareholders are expected to receive $3.65 per share in cash, raising questions about the fairness of the deal which could impact shareholder investment decisions.
- Legal Firm Strength: Recognized as a Top 50 firm in the 2024 ISS Securities Class Action Services Report, Monteverde's strong track record in protecting shareholder rights enhances its reputation and credibility in the market.
- Headquarters Advantage: Based in the Empire State Building, Monteverde & Associates leverages its national presence as a class action securities firm to effectively provide legal support to shareholders, improving accessibility to its services.
- No-Risk Consultation: The firm offers free legal consultations, encouraging shareholders to obtain more information without cost or obligation, thereby increasing trust and reliance on its services among shareholders.
See More
Quipt's Board Faces Scrutiny as Shareholder Plans to Vote Against Directors
- Shareholder Value Erosion: Bradley L. Radoff, a shareholder of Quipt Home Medical Corp., criticized the Board for diluting shareholder value by awarding approximately 6% of the company to insiders after receiving credible acquisition offers, significantly harming shareholder interests.
- Board Credibility Crisis: Radoff pointed out that the Board has failed to execute strategies effectively over the years, leading to a loss of credibility and raising concerns about its management capabilities, which could impact future financing and acquisition opportunities.
- Need for Independent Advisors: Radoff emphasized that the Board should promptly update the market on its efforts and consider hiring truly independent advisors to pursue a value-maximizing sale process, preventing further damage to shareholder interests.
- 2026 Shareholder Meeting Plans: Radoff stated that he intends to vote against all incumbent directors at the 2026 Annual Meeting if the Board continues to jeopardize shareholder value, reflecting shareholder dissatisfaction with the current situation and a pressing demand for change.
See More
Quipt Home Medical to Hold Special Shareholder Meeting
- Special Meeting Announcement: Quipt Home Medical will hold a special shareholder meeting on March 3, 2026, to vote on a proposal to acquire all outstanding shares at $3.65 each, representing a 54% premium over the 30-day VWAP as of December 12, 2025, which is expected to significantly enhance shareholder value.
- Voting Support Agreements: The entire board and executive officers of Quipt, holding approximately 11.3% of the shares, have entered into voting support agreements with the acquirer, committing to vote in favor of the arrangement at the meeting, indicating strong management backing for the transaction.
- Interim Court Order: The Supreme Court of British Columbia issued an interim order on January 23, 2026, authorizing the calling of the meeting and setting procedures for its conduct, providing legal assurance for the arrangement's implementation and ensuring compliance.
- Encouragement for Shareholder Voting: Quipt encourages all shareholders to vote by proxy ahead of the February 27, 2026 deadline at 10:00 a.m. (Eastern Standard Time), ensuring that every shareholder's voice is heard and promoting transparency in decision-making.
See More
Quipt Home Medical to Hold Special Shareholder Meeting
- Special Meeting Announcement: Quipt Home Medical will hold a special shareholder meeting on March 3, 2026, where shareholders will vote on a proposal to sell all outstanding shares for $3.65 each, representing a 54% premium over the 30-day VWAP as of December 12, 2025, which could significantly alter the company's shareholder structure and future direction.
- Voting Support Agreements: The entire board and executive officers of Quipt, holding approximately 11.3% of shares, have entered into voting support agreements with the acquirer, committing to vote in favor of the arrangement resolution, which may bolster shareholder confidence in the transaction.
- Interim Order Received: The Supreme Court of British Columbia issued an interim order on January 23, 2026, authorizing the calling of the meeting and establishing procedures for its conduct, providing legal backing for the arrangement's implementation and ensuring the transaction proceeds smoothly.
- Encouragement for Shareholder Voting: The company urges all shareholders to vote in advance of the February 27, 2026, deadline at 10:00 a.m. (Eastern Standard Time), aiming to enhance shareholder engagement and secure the necessary approvals for the transaction to achieve its strategic objectives.
See More
Ademi Firm Investigates Quipt's $260M Transaction with Kingswood for Fiduciary Breaches
- Investigation Launched: The Ademi Firm is investigating Quipt's transaction with Kingswood for potential breaches of fiduciary duty and legal violations, focusing on whether the Quipt board is fulfilling its responsibilities to all shareholders.
- Transaction Valuation: In this deal, Quipt shareholders will receive $3.65 per share, valuing the company at approximately $260 million, including its existing outstanding debt, indicating a significant impact on the company's financial standing.
- Competition Restrictions: The transaction agreement imposes significant penalties on Quipt for accepting competing bids, which could harm shareholder interests and lead to legal disputes regarding the board's conduct.
- Insider Benefits: Quipt insiders will receive substantial benefits as part of the change of control arrangements, raising concerns about the board's actions and potentially affecting the transparency of corporate governance and shareholder trust.
See More
Quipt Home Medical to Sell for $3.65 per Share to Kingswood and Forager
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Quipt Home Medical Corp.'s sale for $3.65 per share, which may violate federal securities laws and impact shareholder rights.
- Merger Transaction Impact: The merger between Fifth Third Bancorp and Comerica Incorporated will result in Fifth Third shareholders owning approximately 73% of the combined entity, potentially altering shareholder control and corporate governance structures.
- Potential Payment Rights: Generation Bio Co. is being sold for $4.2913 per share, along with a non-transferable contingent value right, which could provide shareholders with additional potential payments, enhancing investment appeal.
- Legal Rights Protection: Halper Sadeh LLC offers free consultations to help shareholders understand their legal rights and options, aiming to secure increased consideration and additional disclosures for affected investors.
See More
Monteverde & Associates Investigates Quipt Home Medical Corp. Sale at $3.65 per Share
- Shareholder Rights Protection: Monteverde & Associates is investigating the sale of Quipt Home Medical Corp. to Kingswood Capital Management, where shareholders are expected to receive $3.65 per share in cash, raising questions about the fairness of the deal which could impact shareholder investment decisions.
- Legal Firm Strength: Recognized as a Top 50 firm in the 2024 ISS Securities Class Action Services Report, Monteverde's strong track record in protecting shareholder rights enhances its reputation and credibility in the market.
- Headquarters Advantage: Based in the Empire State Building, Monteverde & Associates leverages its national presence as a class action securities firm to effectively provide legal support to shareholders, improving accessibility to its services.
- No-Risk Consultation: The firm offers free legal consultations, encouraging shareholders to obtain more information without cost or obligation, thereby increasing trust and reliance on its services among shareholders.
See More
Quipt's Board Faces Scrutiny as Shareholder Plans to Vote Against Directors
- Shareholder Value Erosion: Bradley L. Radoff, a shareholder of Quipt Home Medical Corp., criticized the Board for diluting shareholder value by awarding approximately 6% of the company to insiders after receiving credible acquisition offers, significantly harming shareholder interests.
- Board Credibility Crisis: Radoff pointed out that the Board has failed to execute strategies effectively over the years, leading to a loss of credibility and raising concerns about its management capabilities, which could impact future financing and acquisition opportunities.
- Need for Independent Advisors: Radoff emphasized that the Board should promptly update the market on its efforts and consider hiring truly independent advisors to pursue a value-maximizing sale process, preventing further damage to shareholder interests.
- 2026 Shareholder Meeting Plans: Radoff stated that he intends to vote against all incumbent directors at the 2026 Annual Meeting if the Board continues to jeopardize shareholder value, reflecting shareholder dissatisfaction with the current situation and a pressing demand for change.
See More
